Navigation Links
Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
Date:4/9/2008

NEW YORK, April 9, 2008 /PRNewswire/ -- Intra-Cellular Therapies, Inc., today announced additional preclinical data from its ongoing development programs for ITI-007, the Company's first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM), and ITI-722, a low-dose formulation of ITI-007, which are in development for schizophrenia and sleep disorders, respectively. These new data demonstrate ITI-007 has preclinical activity both in vitro and in vivo as an antidepressant.

ITI-007 acts as a potent inhibitor of the serotonin transporter (SERT), a major target for most antidepressant drugs. To examine whether this in vitro activity could be predictive of behavioral activity in vivo, the antidepressant effect of ITI-007 was investigated using an animal model of depression involving social stress. Repeated treatment of ITI-007 improved performance in this animal model, consistent with antidepressant-like efficacy. The combined actions of ITI-007 as a SERT inhibitor, a 5HT2A receptor antagonist, and a DPPM may provide a unique, antidepressant drug with a more optimal profile, including a lack of sexual side effects common to other antidepressant drugs.

"These studies demonstrate ITI-007 may have antidepressant activity in addition to its potential in treating sleep maintenance insomnia and psychosis in patients," stated Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "We believe ITI-007 represents a unique compound that may have broad use in treating many neuropsychiatric and neurodegenerative disorders where sleep problems, depression, or psychosis are prominent symptoms, including schizophrenia, affective disorders, and Parkinson's disease."

About ITI-007

ITI-007 is an orally available compound which combines potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. As a dopamine receptor phos
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
3. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
6. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
7. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
8. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
9. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
10. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
11. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ), ... the appointment of Joann V. Lofgren to ... Development, effective July 6, 2015. In this role, Ms. ... on the company,s market and product development strategy for ... welcome Joann to the OncoSec team and have her ...
(Date:7/4/2015)... 4, 2015 De ... chemotherapie voor patiënten met niet-resectabele uitgezaaide colorectale ... progressievrije overleving in dat orgaan. ... (mCRC) die alleen binnen de lever is ... overleving (PFS) in de lever dankzij de ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... Mass., Aug. 14 StatSure,Diagnostic Systems, Inc. (OTC Bulletin ... patented, "barrel- test" format for the detection of,antibodies to ... completed,the trials needed for a CLIA waiver application and ... Food & Drug Administration (FDA) for,their review. The Company ...
... Efficacy of LBH589 in ... Myeloma, NORWALK, Conn., Aug. 14 The Multiple ... Phase II,study to determine the efficacy of LBH589 for ... LBH589 is an orally,administered deacetylase inhibitor developed by Novartis ...
Cached Medicine Technology:CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 2CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 3Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 2Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 3
(Date:7/6/2015)... Beach, Virginia (PRWEB) , ... July 06, 2015 ... ... States choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction ... country. For a particular demographic, however, fat reduction has become more than a ...
(Date:7/6/2015)... Pleasant Grove, Utah (PRWEB) , ... July 06, 2015 , ... ... of Kirk Jowers to its executive management team. Most recently, Jowers held the position ... held for ten years. , After spending a decade building the institute, Jowers states ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and genomics projects have ... field to access and use this “Big Data” to improve health and cut costs ... Officer of the Mount Sinai Health System in New York City. Physicians will have ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a new community program in ... Save Our Youth and announced a new charity campaign to raise funds in support ... and drug abuse. Livonia Save Our Youth is a coalition created especially to educate ...
(Date:7/6/2015)... ... July 06, 2015 , ... Promero, ... Technologies selected Aspect Software Unified IP contact center solution hosted by Promero. ... Unified IP as its future call center platform. , Promero will implement ...
Breaking Medicine News(10 mins):Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3
... PureCircle (LSE: PURE), the world,s leading producer of ... announce the launch of Revive Supplement Water(TM) in New ... vitamin-enhanced beverage to feature a pure stevia all-natural sweetener. ... high-purity Reb A. , PureCircle VP Sales Asia Pacific, ...
... Biofield therapies, which claim to use subtle energy to ... for reducing the intensity of pain in a number ... agitated behaviors in dementia, over and above what standard ... Dr. Shamini Jain, from the UCLA Division of Cancer ...
... While most ... few are concerned about the best method to dry their hands. This is why Cascades ... flu, to inform the Canadian population of the undeniable advantages of paper hand towels. ... Candiac, Quebec (PRWEB) October 29, ...
... Cancer is not strictly a "human" condition. As the No. ... of pets each year. This November, Veterinary Pet Insurance Co. ... insurance, will seek to increase awareness about the prevalence, detection ... Cancer Awareness Month. To raise funds for pet cancer research, ...
... October 29 The launch of latest diabetes,healthcare web-portal ... and diabetic statistics and share this information with their,doctor, ... trends and a,relevant lifestyle & diabetic health management tool. ... undertaken as India, with over 50 million,diabetics is currently ...
... easier, more effective therapy for seasonal affective disorder , ... hours dwindle, people with seasonal affective disorder (SAD) can ... new study suggests one type of remedy may work ... Cognitive behavioral therapy specially designed to treat people with ...
Cached Medicine News:Health News:Biofield therapies: Helpful or full of hype? 2Health News:Cascades Launches Information Campaign on Hand Drying 2Health News:Cascades Launches Information Campaign on Hand Drying 3Health News:November Marks Fifth Annual National Pet Cancer Awareness Month 2Health News:November Marks Fifth Annual National Pet Cancer Awareness Month 3Health News:CHEENY KUM: The Mobile - Online Way to Monitor Diabetes 2Health News:Psychotherapy Beats Light Treatment for SAD 2Health News:Psychotherapy Beats Light Treatment for SAD 3
... with a low-profile, roomy pouch to ... site during arthroscopic surgery. Available with ... drainage. , ,The arthroscopy sheets ... pack, or in custom trays. For ...
The Abbott Commander is an automated, high-throughput immunoassay testing system. The Commander System consists of the Flexible Pipetting Center, the Parallel Processing Center, and the Dynamic Incub...
... Sequence Detection System is a complete, ... quantitates nulceic acid sequences. In real-time ... product is made possible by combining ... software in a single instrument. Quantitative ...
... CELL-DYN 3200 sets a benchmark of ... scatter for WBC, RBC, PLT and ... the needs of today's laboratory. The ... differential analysis, automated sample handling, comprehensive ...
Medicine Products: